Camurus and Lilly Sign Agreement for Global Development of Long-Acting FluidCrystal® Incretins
Wednesday, June 04, 2025
Camurus and Eli Lilly and Company have entered into a collaboration and licence agreement that gives Lilly exclusive global rights to develop, produce, and market long-acting incretin-based treatments for cardiometabolic conditions using Camurus' FluidCrystal® technology. The partnership includes up to four drug compounds owned by Lilly.
The agreement enables Camurus to support wider use of its FluidCrystal delivery system in treating chronic conditions such as obesity and diabetes, while the company continues to focus commercially on central nervous system and rare disease areas.
Under the terms of the agreement, Camurus may receive up to USD 290 million in upfront, development, and regulatory milestone payments. Additionally, the company could receive up to USD 580 million in sales-related milestone payments, along with tiered mid-single digit royalties based on global net sales.
Source: prnewswire.com
